13 results about "Protein subunit" patented technology

The application relates to preparation and application of a giant Eimeria nanosubunit vaccine. The nanosubunit vaccine PLGA-rEmLPL is prepared by coating E. maxima Treg-induced molecule EmLPL recombinant protein (rEmLPL) with PLGA nanoparticles. The immunoprotective effects of the subunit vaccine rEmLPL and the nanosubunit vaccine PLGA-rEmLPL are evaluated through animal immunoprotection tests, and the results show that both the vaccines can produce good immunoprotective effects on E. maxima infection. After the recombinant protein subunit vaccine rEmLPL is coated with the PLGA nanoparticles, the immunoprotective effect of the nanosubunit vaccine PLGA-rEmLPL on animals is improved compared with that of the subunit vaccine rEmLPL.

Methods of treating preventing and / or substantially reducing a Pseudomonas aeruginosa (PA) infection and / or a Staphylococcus aureus (SA) infection by administration of a bivalent protein subunit-based vaccine are described. The vaccine can protect subjects with a prior history of exposure to SA from a new exposure to PA or SA, including methicillin resistant SA (MRSA), as well as being able to protecting with no prior exposure to a SA infection. Vaccine formulations are also described.

This invention relates to the field of pharmaceutical technology, and more particularly to fusion proteins of human heavy chain ferritin or its variants with polyhedral or granular proteins and their applications. This invention fuses a ferritin variant with a baculovirus polyhedral protein subunit to obtain particles with a diameter <20 nm, consisting of a polyhedral protein outer layer and a ferritin inner layer. The particles have an outer diameter of 17 nm, an inner lumen of 13 nm, and are positively charged. pH adjustment enables the depolymerization and recombination of the outer and inner layers, allowing the encapsulation of negatively charged insulin molecules with a diameter >8 nm. Proteins fused with polyhedral or granular protein subunits to wild-type or mutant ferritin can self-assemble into bilayer nanoparticles. The inner layer is a cage-like structure with a positive or negatively charged lumen and a size of 8 nm or 13 nm; the outer layer is a polyhedral or granular protein layer, exhibiting resilience, resistant to high temperatures and dehydration, and resistant to digestion by pepsin and trypsin. These nanoparticles can serve as oral carriers for various active molecules.

Provided are methods of producing an isolate of soluble proteins from moringa leaves, and methods of preparing a powder of soluble proteins from moringa leaves. Also provided are compositions-of-matter comprising a chlorophyll-free preparation of soluble proteins of moringa leaves, wherein the soluble proteins comprise large and small Rubisco protein subunits, a preparation comprising the composition-of-matter, and edible, cosmetic and pharmaceutical compositions comprising same.

The invention relates to a formate dehydrogenase mutant and application thereof, and belongs to the field of enzyme engineering and carbon dioxide reduction. The invention provides a formate dehydrogenase mutant. The formate dehydrogenase mutant comprises a formate dehydrogenase catalytic subunit FdhA, an electron transport subunit FdhB and a membrane anchoring protein subunit FdhC, compared with formate dehydrogenase, the formate dehydrogenase mutant has the advantages that a membrane anchor protein subunit FdhC is deleted, or the membrane anchor protein subunit FdhC and an electron transport subunit FdhB are deleted. Compared with the existing formate dehydrogenase, the formate dehydrogenase mutant provided by the invention has high activity and can tolerate oxygen at the same time. The formate dehydrogenase mutant provided by the invention shows huge potential value in the carbon dioxide immobilization industry.

This invention provides a composition and method for genomic modification of target sequences in the cellular genome using a novel Cas endonuclease. [Solution] An effective system is provided for modifying or altering target sequences in the genome of a cell or organism using a guide polynucleotide / endonuclease system. Also provided are novel effectors and endonuclease systems, such as guide polynucleotide / endonuclease systems containing endonucleases, and elements containing such systems. Furthermore, compositions and methods are provided for guide polynucleotide / endonuclease systems comprising at least one endonuclease optionally covalently or noncovalently linked to or assembled with at least one further protein subunit.

The application relates to preparation and application of a nano-subunit vaccine for preventing chicken coccidiosis. The nano-subunit vaccine PLGA-rEmTregIM-1 is prepared by coating a giant Eimeria maxima Treg inducing molecule EmTregIM-1 recombinant protein (rEmTregIM-1) with PLGA nanoparticles. The immunoprotective effects of the subunit vaccine rEmTregIM-1 and the nano-subunit vaccine PLGA-rEmTregIM-1 are evaluated through animal immunoprotection tests, and the results show that both the vaccines can produce partial immunoprotections for the giant Eimeria maxima infection. After the recombinant protein subunit vaccine rEmTregIM-1 is coated with the PLGA nanoparticles, the nano-subunit vaccine PLGA-rEmTregIM-1 has an improved immunoprotection effect on animals compared with the subunit vaccine rEmTregIM-1.

The invention discloses a canine anti-cystic hydatid double-antigen recombinant protein subunit vaccine and a preparation method thereof, and relates to the technical field of biological medicines. The canine anti-cystic hydatid double-antigen recombinant protein subunit vaccine takes recombinant proteins rEg 05752 and rEg 09809 as core double antigens, and the recombinant proteins rEg 05752 and rEg 09809 do not have transmembrane regions and signal peptides and contain a plurality of B cell antigen epitopes. After a beagle is immunized, a body can be efficiently induced to generate a specific IgG antibody, the titer of the antibody reaches a peak value 35 days after immunization and still maintains a relatively high level after attack, and meanwhile, Th1 / Th2 type mixed immune response is remarkably activated, so that the levels of cell factors such as IL-2, IFN-gamma, IL-4 and IL-5 are greatly improved. The immune protection effect is remarkable, and a safe and efficient novel technical means is provided for source prevention and control of the cystic echinococcosis.

The invention discloses a protein subunit vaccine adjuvant aiming at pathogenic bacteria of pelteobagrus fulvidraco, a preparation method and application, the protein subunit vaccine adjuvant is coded by a nucleotide sequence, the nucleotide sequence is shown as SEQ ID NO.1, the protein coded by the nucleotide sequence is the protein subunit vaccine adjuvant, and the protein subunit vaccine adjuvant is a protein subunit vaccine adjuvant. The protein subunit vaccine adjuvant comprises an amino acid as shown in SEQ ID NO. 2. The protein subunit vaccine adjuvant is pelteobagrus fulvidraco IL6 protein and can be used as a vaccine adjuvant, the immune effect of a pelteobagrus fulvidraco vaccine is remarkably improved, specifically, the activity of lysozyme in serum and the content of complement C3 are improved, the expression of immune-related genes (such as IL-1beta and TNF-alpha) is enhanced, and the protection rate of the vaccine on edwardsiella ictaluri after toxin attacking is remarkably increased. The invention further discloses a combined immune composition composed of the IL6 protein and the edwardsiella ictaluri OmpC protein, and application of the combined immune composition in preparation of edwardsiella ictaluri subunit vaccines.

The present disclosure relates to fusion proteins comprising a mutant IL-2 polypeptide subunit and one or two antigen binding domains (e.g., VHH antibodies) that specifically bind to an antigen expressed on the surface of immune cells such as tumor reactive T cells expressing CD8 and / or PD1. The fusion can also comprise a half-life extending protein subunit such as an Ig1 Fc region monomer polypeptide. The present disclosure also relates to the use of these fusion proteins as therapeutic agents, for example, in pharmaceutical compositions for treating cancer and autoimmune disorders.

This invention belongs to the field of genetic engineering vaccine technology, specifically relating to a subunit vaccine against *Avibacterium avium* (type A) in chickens, its preparation method, and its application. The subunit vaccine comprises the OMA87 protein, with a size of 97.15 kDa, the gene sequence of which is shown in SEQ.ID.NO.4, and the amino acid sequence in SEQ.ID.NO.5. After induction of expression, the OMA87 protein was purified and detoxified to obtain a semi-finished antigen with a purity of over 50% and an endotoxin content below 2500 EU / mL. Using white oil adjuvant, a qualified OMA87 protein subunit vaccine was prepared through emulsification, thus becoming the *Avibacterium avium* subunit vaccine. This vaccine demonstrates good safety in broilers and laying hens, producing high and long-lasting antibody levels, providing a method for preventing *Avibacterium avium* infection in broilers and laying hens.

This invention belongs to the field of biotechnology, specifically relating to a method and application for the isolation and preparation of detached spike protein S1 subunits. This invention successfully isolates detached S1 protein subunits using PEG precipitation, a rapid, convenient, and reliable method that yields structurally correct and stable S1 units. By simulating the binding of the spike protein to ACE2 during coronavirus infection, the S1 subunit is detached. The tag carried by the S1 subunit is then used to isolate and purify the naturally detached S1 subunit, resulting in structurally correct and stable S1 units. The S1 subunit protein is a core functional unit for viral invasion; drug design based on its naturally detached structure can efficiently inhibit viral fusion and is an important target for screening blocking agents (such as small molecules, antibodies, and nucleic acid aptamers). The detached S1 subunit retains an intact antigenic epitope and can be used as a core reagent in detection methods such as ELISA, immunochromatography, and biosensors for detecting viruses or neutralizing antibodies.

The present invention provides a chimeric protein subunit comprising, linked to each other, (a) a D12 subunit of an RNA capping enzyme or a functional fragment thereof, or a variant having at least 90% sequence identity thereto and having the activity of a D12 subunit, and (b) an RNA cap structure 2'-O-methyltransferase or a functional fragment thereof, or a variant having at least 90% sequence identity thereto and having the activity of an RNA cap structure 2'-O-methyltransferase. The present invention also provides a chimeric protein comprising said chimeric protein subunit and a D1 subunit of an RNA capping enzyme or a functional fragment thereof.